BRCA Mutations in Prostate Cancer: Assessment, Implications and Treatment Considerations
Related Experiment Video
Updated: Oct 10, 2025
Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
Published on: November 2, 2013
Sidrah Shah1, Rachelle Rachmat2, Synthia Enyioma3
1Department of Palliative Care, Guy's and St Thomas' Hospital, Great Maze Pond, London SE1 9RT, UK.
Abstract:
Prostate cancer ranks fifth in cancer-related mortality in men worldwide. DNA damage is implicated in cancer and DNA damage response (DDR) pathways are in place against this to maintain genomic stability. Impaired DDR pathways play a role in prostate carcinogenesis and germline or somatic mutations in DDR genes have been found in both primary and metastatic prostate cancer. Among these, BRCA mutations have been found to be especially clinically relevant with a role for germline or somatic testing. Prostate cancer with DDR defects may be sensitive to poly(ADP-ribose) polymerase (PARP) inhibitors which target proteins in a process called PARylation. Initially they were used to target BRCA-mutated tumor cells in a process of synthetic lethality. However, recent studies have found potential for PARP inhibitors in a variety of other genetic settings. In this review, we explore the mechanisms of DNA repair, potential for genomic analysis of prostate cancer and therapeutics of PARP inhibitors along with their safety profile.
Insights
Prostate cancer
Area of Science:
- Oncology
- Genetics
- Molecular Biology
Background:
- Prostate cancer is a leading cause of male cancer mortality globally.
- DNA damage response (DDR) pathways are crucial for maintaining genomic stability.
- Defects in DDR pathways and mutations in DDR genes are implicated in prostate cancer development and progression.
Purpose of the Study:
- To review DNA repair mechanisms in prostate cancer.
- To explore the potential of genomic analysis in prostate cancer.
- To discuss the therapeutic applications and safety of poly(ADP-ribose) polymerase (PARP) inhibitors.
Main Methods:
- Literature review of DNA repair pathways.
- Analysis of genomic alterations in prostate cancer.
- Review of clinical studies on PARP inhibitors.
Main Results:
- BRCA mutations are clinically significant in prostate cancer, indicating potential for targeted therapies.
- Prostate cancers with DDR defects may respond to PARP inhibitors via synthetic lethality.
- PARP inhibitors show promise in various genetic contexts beyond BRCA mutations.
Conclusions:
- Understanding DNA repair and genomic alterations is key for prostate cancer treatment.
- PARP inhibitors represent a promising therapeutic strategy for specific prostate cancer subtypes.
- Further research into PARP inhibitor efficacy and safety is warranted.
Related Concept Videos
01:25Mutagenicity and Carcinogenicity
02:23Abnormal Proliferation
01:20The Retinoblastoma Gene
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...